D. E. Shaw & Co. Inc. Purchases Shares of 105,130 Anavex Life Sciences Corp. (NASDAQ:AVXL)

D. E. Shaw & Co. Inc. purchased a new position in Anavex Life Sciences Corp. (NASDAQ:AVXL) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 105,130 shares of the biotechnology company’s stock, valued at approximately $1,129,000. D. E. Shaw & Co. Inc. owned 0.12% of Anavex Life Sciences as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its position in Anavex Life Sciences by 2.9% during the third quarter. JPMorgan Chase & Co. now owns 42,565 shares of the biotechnology company’s stock valued at $242,000 after purchasing an additional 1,191 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Anavex Life Sciences by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,980 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 1,671 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Anavex Life Sciences by 102.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 1,708 shares during the last quarter. Foster Victor Wealth Advisors LLC lifted its holdings in shares of Anavex Life Sciences by 5.6% during the 4th quarter. Foster Victor Wealth Advisors LLC now owns 37,663 shares of the biotechnology company’s stock worth $405,000 after acquiring an additional 2,000 shares during the last quarter. Finally, Opus Capital Group LLC grew its position in Anavex Life Sciences by 6.1% in the fourth quarter. Opus Capital Group LLC now owns 34,700 shares of the biotechnology company’s stock worth $373,000 after acquiring an additional 2,000 shares in the last quarter. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Stock Performance

Shares of AVXL opened at $7.53 on Friday. Anavex Life Sciences Corp. has a fifty-two week low of $3.51 and a fifty-two week high of $14.44. The firm has a market cap of $642.85 million, a price-to-earnings ratio of -13.69 and a beta of 0.82. The firm has a 50 day moving average price of $8.75 and a 200-day moving average price of $9.12.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. During the same quarter in the prior year, the company earned ($0.13) earnings per share. As a group, equities research analysts predict that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on AVXL shares. HC Wainwright restated a “buy” rating and set a $42.00 price target on shares of Anavex Life Sciences in a research report on Monday, April 7th. D. Boral Capital reiterated a “buy” rating and set a $46.00 price objective on shares of Anavex Life Sciences in a research report on Monday, April 7th.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.